Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis
In this Phase 1 study, PRX004 was found to be generally safe and well tolerated across all dose levels.
- In this Phase 1 study, PRX004 was found to be generally safe and well tolerated across all dose levels.
- As previously reported, the long-term extension portion of the Phase 1 study was disrupted by the COVID-19 pandemic.
- In addition, the change in NIS for each of these evaluable patients was more favorable than the published historical data.
- These positive results were observed in patients with or without concomitant use of stabilizer therapy.